Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Inc.

www.pfizer.com

Latest From Pfizer Inc.

Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer

KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of metastastic breast cancer.

Clinical Trials ImmunoOncology

10 Things For Pfizer's New CEO To Worry About

Albert Bourla will face opportunities and potential pitfalls.
Strategy Companies

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

This month a handful of biosimilars of the world’s top-selling drug, Humira (adalimumab), are due to launch in Europe. They will not topple the $18 billion behemoth. But they will do some damage, as Europe’s cash-strapped payers ready themselves to embrace these cheaper lookalikes. 

Biosimilars Market Intelligence

Can Lilly's Olumiant Prickle Xeljanz In India?

Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
India Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register